Skip to main content
. 2018 Apr 23;2018:5346272. doi: 10.1155/2018/5346272

Figure 2.

Figure 2

Effects of MEKT1, rosiglitazone, and pioglitazone on Pomc promoter activity in AtT20 cells. AtT20 cells transiently transfected with 300 ng full length rPomc-Luc (−703/+58-luc) and 100 ng pRSV-β-gal were treated with MEKT1, rosiglitazone (Rosi), and pioglitazone (Pio) (1 nM, 10 nM, 100 nM, 1 μM, or 10 μM) or 0.1% DMSO (vehicle control) for 24 hours. Data are expressed as percentages (100%) of control. Each point represents mean ± SEM (n = 4). ∗∗P < 0.01, ∗∗∗P < 0.001 versus control.